Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
1. Xenon Pharmaceuticals announced an upcoming investor webinar on pain treatments.
2. The webinar will discuss Kv7 and Nav1.7 programs targeting non-opioid pain relief.
3. Xenon is developing leading treatments currently in Phase 3 clinical trials.
4. Webinar is scheduled for October 6, 2025, from 11:30 AM to 12:30 PM ET.
5. Live webcast and future access available via the company's website.
The focus on innovative pain treatments may attract investor interest. Historical trends indicate strong market response to potential non-opioid therapies.
How important is it?
The webinar highlights key programs, fostering investor interest and potentially positively influencing stock price.
Why Short Term?
The webinar can have an immediate effect on investor sentiment leading to short-term price movement.
VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain.
Webinar:
Developing Novel Non-Opioid Treatments for Pain: An Overview of Xenon's Nav1.7 and Kv7 Programs
Questions may be submitted (via chat function) during the live webinar or submitted in advance via email to investors@xenon-pharma.com.
A live webcast of the webinar will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed date and time are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
